COVID-19 vaccines versus pediatric hospitalization

Jaime S Rosa Duque; Daniel Leung; Ka Man Yip; Derek H L Lee; Hung-Kwan So; Wilfred H S Wong; Yu Lung Lau

doi:10.1016/j.xcrm.2023.100936

COVID-19 vaccines versus pediatric hospitalization

Cell Rep Med. 2023 Feb 21;4(2):100936. doi: 10.1016/j.xcrm.2023.100936. Epub 2023 Jan 23.

Authors

Jaime S Rosa Duque¹, Daniel Leung¹, Ka Man Yip¹, Derek H L Lee¹, Hung-Kwan So¹, Wilfred H S Wong², Yu Lung Lau³

Affiliations

¹ Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China.
² Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: whswong@hku.hk.
³ Department of Paediatrics and Adolescent Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: lauylung@hku.hk.

Abstract

Vaccine effectiveness of BNT162b2 and CoronaVac against COVID-19-associated hospitalization and moderate-to-severe disease due to SARS-CoV-2 Omicron BA.2 is studied from the 1.36 million doses administered to 766,601 of 953,400 children aged 3-11 years and adolescents aged 12-18 years in Hong Kong as of April 2022. These vaccines confer substantial protection.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
BNT162 Vaccine
COVID-19 Vaccines*
COVID-19*
Child
Hospitalization
Humans
SARS-CoV-2

Substances

sinovac COVID-19 vaccine
COVID-19 Vaccines
BNT162 Vaccine
dioctadecylamidospermine